Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 21

Sort by

Sort Order Select

Journal Articles

Establishing Distinct Cytokine Signatures Differentiating between Acute Myeloid Leukemia, Myelodysplastic Syndrome, and Chip Using Bone Marrow RNA or Cell-Free RNA (cfRNA)

Maher Albitar, Sally Agersborg, Ahmad Charifa, Hong Zhang, Andrew Ip, Katherine Linder, Andrew L Pecora, Jamie Koprivnikar, Andre Goy, James McCloskey

Blood (2024) 144 (Supplement 1): 4295.

https://doi.org/10.1182/blood-2024-203870

Published: 2024

Journal Articles

Augmented Hyper-CVAD (AHCVAD), a Pediatric Inspired Regimen for Adults Younger Than 50 Years of Age with Acute Lymphoblastic Leukemia (ALL), Yields High Rates of MRD Negativity, Favorable 3-Year Overall Survival Regardless of Allogeneic Stem Cell Transplant (ASCT): A Single Center Experience

Sarvarinder Kaur Gill, Geeny Lee, Joelle Rubin, Shuqi Wang, Jamie Koprivnikar, Katherine Linder, James McCloskey

Blood (2024) 144 (Supplement 1): 1448.

https://doi.org/10.1182/blood-2024-210149

Published: 2024

Journal Articles

No Improvement in the Age Adjusted Mortality of Older Adults with Acute Lymphoblastic Leukemia Despite the Availability of Blinatumumab, Inotuzumab and Novel TKIs : A 1999-2020 Analysis in the United States

Tony Varughese, Maciej Kabat, Eli Zolotov, Jamie Koprivnikar

Blood (2023) 142 (Supplement 1): 1465.

https://doi.org/10.1182/blood-2023-188366

Published: 2023

Journal Articles

Unveiling Alarming Trends: Worsening All Cause Mortality in US Adults over 25 with Amyloid 1999-2020 Analysis

Maciej Kabat, Tony Varughese, Eli Zolotov, Jamie Koprivnikar

Blood (2023) 142 (Supplement 1): 2034.

https://doi.org/10.1182/blood-2023-188372

Published: 2023

Journal Articles

Frontline Aspacytarabine with Venetoclax for Older/Unfit Patients with Acute Myeloid Leukemia: Preliminary Results of a Phase 1 Study

Jessica K. Altman, Yasmin Abaza, Michael Keng, Abhishek Maiti, Jamie Koprivnikar, Shoshi Tessler, Chen Blumberg, Liat Flaishon, Ruth Ben Yakar

Blood (2023) 142 (Supplement 1): 5970.

https://doi.org/10.1182/blood-2023-185694

Published: 2023

Journal Articles

Decades of Improvement in Cardiovascular Morbidity and Mortality in Leukemia Patients Reversed in 2020: Covid? Novel Agents? Neither?

Tony Varughese, Eli Zolotov, Maciej Kabat, Jamie Koprivnikar

Blood (2023) 142 (Supplement 1): 7445.

https://doi.org/10.1182/blood-2023-188331

Published: 2023

Journal Articles

COVID-19 Related Mortality Does Not Correlate with Vaccine Availability in Leukemia Patients: 2020-2023 Analysis in the United States

Tony Varughese, Maciej Kabat, Eli Zolotov, Jamie Koprivnikar

Blood (2023) 142 (Supplement 1): 5808.

https://doi.org/10.1182/blood-2023-182557

Published: 2023

Journal Articles

Deregulation of HLA-Class I and Class II Genes in Chip, MDS, and Acute Leukemia and Similarity between Chip and MDS in HLA Profile

Maher Albitar, Hong Zhang, Andrew Ip, Gustavo A. Rivero, Wanlong Ma, James McCloskey, Katherine Linder, Jeffrey Justin Estella, Jamie Koprivnikar, Ahmad Charifa, Arash Mohtashamian, Andrew L Pecora, Andre Goy

Blood (2023) 142 (Supplement 1): 5688.

https://doi.org/10.1182/blood-2023-187606

Published: 2023

Journal Articles

Using Next Generation Sequencing of Flow Cytometry CD Markers and Machine Learning As a Replacement to Flow Cytometry Analysis for the Diagnosis of Hematologic Neoplasms

Maher Albitar, Hong Zhang, Andrew Ip, Wanlong Ma, James McCloskey, Katherine Linder, Jeffrey Justin Estella, Jamie Koprivnikar, Noa Biran, David S. Siegel, Ahmad Charifa, Arash Mohtashamian, Andrew L Pecora, Andre Goy

Blood (2023) 142 (Supplement 1): 3654.

https://doi.org/10.1182/blood-2023-187041

Published: 2023

Journal Articles

An 8-year pragmatic observation evaluation of the benefits of allogeneic HCT in older and medically infirm patients with AML

Blood (2023) 141 (3): 295–308.

https://doi.org/10.1182/blood.2022016916

Published: 2023

Includes: Supplemental data

Journal Articles

DNA and RNA Profiles in Machine Learning Algorithm to Predict Which Patients with AML/MDS Will Respond to Venetoclax-Based Therapy

Maher Albitar, Andrew Ip, Andre H. Goy, Katherine Linder, Jeffrey Justin Estella, Ahmad Charifa, Wanlong Ma, Andrew L. Pecora, Jamie Koprivnikar, James McCloskey

Blood (2022) 140 (Supplement 1): 6270–6271.

https://doi.org/10.1182/blood-2022-167406

Published: 2022

Journal Articles

Reliability of Cell-Free DNA (cfDNA) Next Generation Sequencing in Predicting Chromosomal Structural Abnormalities and Cytogenetic-Risk Stratification of Patients with Myeloid Neoplasms

Maher Albitar, Andrew Ip, Andre H. Goy, Jeffrey Justin Estella, Ivan De Dios, Wanlong Ma, Andrew L. Pecora, Jamie Koprivnikar, James K McCloskey

Blood (2021) 138 (Supplement 1): 3463.

https://doi.org/10.1182/blood-2021-148164

Published: 2021

Journal Articles

Aspacytarabine (BST-236) As Monotherapy Is Safe, Well-Tolerated and Effective for the Treatment of Adults with Newly Diagnosed Acute Myeloid Leukemia Unfit for Intensive Therapy. Results of a Phase 2 Study

Blood (2021) 138 (Supplement 1): 1273.

https://doi.org/10.1182/blood-2021-149361

Published: 2021

Journal Articles

Multisite 11-year experience of less-intensive vs intensive therapies in acute myeloid leukemia

Blood (2021) 138 (5): 387–400.

https://doi.org/10.1182/blood.2020008812

Published: 2021

Includes: Supplemental data

Journal Articles

Clinical Activity of CC-90009, a Cereblon E3 Ligase Modulator and First-in-Class GSPT1 Degrader, As a Single Agent in Patients with Relapsed or Refractory Acute Myeloid Leukemia (R/R AML): First Results from a Phase I Dose-Finding Study

Blood (2019) 134 (Supplement_1): 232.

https://doi.org/10.1182/blood-2019-123966

Published: 2019

Journal Articles

Cpit (Check Point Inhibitor Trial) 002: Phase I Study of Single-Agent and Combined Checkpoint Inhibition (CI) after Allogenic Hematopoietic Stem Cell Transplantation (alloHCT) in Patients at High Risk for Post-Transplant Recurrence

Jamie Koprivnikar, MD, James K McCloskey, MD, Rena Feinman, PhD, Robert Korngold, PhD, Michele L. Donato, MD, Scott D. Rowley, MD, Themba Nyirenda, PhD, Andrew L. Pecora, MD

Blood (2019) 134 (Supplement_1): 5618.

https://doi.org/10.1182/blood-2019-132025

Published: 2019

Journal Articles

Combined Venetoclax and Hypomethylating Agent (HMA) Therapy Induces High Response Rates in Patients with Myelodysplastic Syndrome Including Patients Previously Failing HMA

Brian J Ball, Christopher Famulare, MS, Eytan M. Stein, MD, Martin S. Tallman, MD, Saar I. Gill, MD PhD, Benjamin M Manning, MD PhD, Jamie Koprivnikar, MD, James McCloskey, MD, Rebecca Testi, NP-C, BSN, RN, MSN, OCN, Najla Al Ali, M.Sc, David A Sallman, MD, Eric Padron, MD, Aaron D Goldberg, MD PhD, Rami S. Komrokji, MD

Blood (2019) 134 (Supplement_1): 4241.

https://doi.org/10.1182/blood-2019-125113

Published: 2019

Journal Articles

Blinatumomab in Combination with Tyrosine Kinase Inhibitors Safely and Effectively Induces Rapid, Deep, and Durable Molecular Responses in Relapsed and Refractory Philadelphia Positive Acute Leukemias

James K McCloskey, MD, Joelle Gagnon, NP, Tara McCabe, FNP-C, MSN, RN, BSN, Jocelyn Charlon, MS, AGPCNP-BC, Shuqi Wang, MSc, Ruzong Fan, Stuart L. Goldberg, MD, Jamie Koprivnikar, MD

Blood (2019) 134 (Supplement_1): 3812.

https://doi.org/10.1182/blood-2019-131838

Published: 2019

Journal Articles

Pharmacodynamic Responses to CC-90009, a Novel Cereblon E3 Ligase Modulator, in a Phase I Dose-Escalation Study in Relapsed or Refractory Acute Myeloid Leukemia (R/R AML)

Jinhong Fan, Hongbin Wang, Suzana Couto, Tsun-Wen Sheena Yao, Geoffrey L. Uy, MD, Amer M. Zeidan, MBBS, MHS, Mark D. Minden, Pau Montesinos, Daniel J. DeAngelo, Jessica K. Altman, Jamie Koprivnikar, MD, Paresh Vyas, MD PhD, Yngvar Fløisand, María Belén Vidriales, Bjørn Tore Gjertsen, Tonia J. Buchholz, Michael Pourdehnad, Daniel W. Pierce

Blood (2019) 134 (Supplement_1): 2547.

https://doi.org/10.1182/blood-2019-124291

Published: 2019

Journal Articles

One Size May Not Fit All for TKI Dosing in Chronic Phase CML—Deep Molecular Responses Despite Dose Reduction

James K McCloskey, MD, Genique Stanislaus, ANP, Yen-Hong Kuo, PhD, Jamie Koprivnikar, MD

Blood (2018) 132 (Supplement 1): 5448.

https://doi.org/10.1182/blood-2018-99-119971

Published: 2018

NARROW

Establishing Distinct Cytokine Signatures Differentiating between Acute Myeloid Leukemia, Myelodysplastic Syndrome, and Chip Using Bone Marrow RNA or Cell-Free RNA (cfRNA)

Augmented Hyper-CVAD (AHCVAD), a Pediatric Inspired Regimen for Adults Younger Than 50 Years of Age with Acute Lymphoblastic Leukemia (ALL), Yields High Rates of MRD Negativity, Favorable 3-Year Overall Survival Regardless of Allogeneic Stem Cell Transplant (ASCT): A Single Center Experience

No Improvement in the Age Adjusted Mortality of Older Adults with Acute Lymphoblastic Leukemia Despite the Availability of Blinatumumab, Inotuzumab and Novel TKIs : A 1999-2020 Analysis in the United States

Unveiling Alarming Trends: Worsening All Cause Mortality in US Adults over 25 with Amyloid 1999-2020 Analysis

Frontline Aspacytarabine with Venetoclax for Older/Unfit Patients with Acute Myeloid Leukemia: Preliminary Results of a Phase 1 Study

Decades of Improvement in Cardiovascular Morbidity and Mortality in Leukemia Patients Reversed in 2020: Covid? Novel Agents? Neither?

COVID-19 Related Mortality Does Not Correlate with Vaccine Availability in Leukemia Patients: 2020-2023 Analysis in the United States

Deregulation of HLA-Class I and Class II Genes in Chip, MDS, and Acute Leukemia and Similarity between Chip and MDS in HLA Profile

Using Next Generation Sequencing of Flow Cytometry CD Markers and Machine Learning As a Replacement to Flow Cytometry Analysis for the Diagnosis of Hematologic Neoplasms

An 8-year pragmatic observation evaluation of the benefits of allogeneic HCT in older and medically infirm patients with AML

DNA and RNA Profiles in Machine Learning Algorithm to Predict Which Patients with AML/MDS Will Respond to Venetoclax-Based Therapy

Reliability of Cell-Free DNA (cfDNA) Next Generation Sequencing in Predicting Chromosomal Structural Abnormalities and Cytogenetic-Risk Stratification of Patients with Myeloid Neoplasms

Aspacytarabine (BST-236) As Monotherapy Is Safe, Well-Tolerated and Effective for the Treatment of Adults with Newly Diagnosed Acute Myeloid Leukemia Unfit for Intensive Therapy. Results of a Phase 2 Study

Multisite 11-year experience of less-intensive vs intensive therapies in acute myeloid leukemia

Clinical Activity of CC-90009, a Cereblon E3 Ligase Modulator and First-in-Class GSPT1 Degrader, As a Single Agent in Patients with Relapsed or Refractory Acute Myeloid Leukemia (R/R AML): First Results from a Phase I Dose-Finding Study

Cpit (Check Point Inhibitor Trial) 002: Phase I Study of Single-Agent and Combined Checkpoint Inhibition (CI) after Allogenic Hematopoietic Stem Cell Transplantation (alloHCT) in Patients at High Risk for Post-Transplant Recurrence

Combined Venetoclax and Hypomethylating Agent (HMA) Therapy Induces High Response Rates in Patients with Myelodysplastic Syndrome Including Patients Previously Failing HMA

Blinatumomab in Combination with Tyrosine Kinase Inhibitors Safely and Effectively Induces Rapid, Deep, and Durable Molecular Responses in Relapsed and Refractory Philadelphia Positive Acute Leukemias

Pharmacodynamic Responses to CC-90009, a Novel Cereblon E3 Ligase Modulator, in a Phase I Dose-Escalation Study in Relapsed or Refractory Acute Myeloid Leukemia (R/R AML)

One Size May Not Fit All for TKI Dosing in Chronic Phase CML—Deep Molecular Responses Despite Dose Reduction

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only